Nonprofit · EIN 85-0837695
SUBCUTANEOUS DRUG DEVELOPMENT & DELIVERY CONSORTIUM INC
Tax-exempt · BEAVERTON, OR 97003
Financials
| Year ended | Form | Revenue | Expenses | Net income | Total assets | Liabilities | Net assets |
|---|---|---|---|---|---|---|---|
| December 31, 2025 | 990 | $1,042,500 | $862,745 | $179,755 | $1,406,406 | $373,267 | $1,033,139 |
| December 31, 2024 | 990 | $719,723 | $491,843 | $227,880 | $1,156,608 | $303,224 | $853,384 |
| December 31, 2023 | 990 | $760,000 | $769,199 | -$9,199 | $901,226 | $275,722 | $625,504 |
Financial details: 990 for the year ended December 31, 2025
Revenue
- Contributions, gifts and grants
- $0
- Program service revenue
- $1,042,500
- Investment income
- $0
- Other revenue
- $0
Expenses
- Grants and similar amounts paid
- $10,000
- Salaries, compensation and benefits (total)
- $0
- Professional fundraising fees
- $0
- Legal fees
- $21,834
- Accounting fees
- $1,808
- Depreciation
- $40,472
Balance sheet and other
- Total assets, start of year
- $1,156,608
- Total assets, end of year
- $1,406,406
- Total liabilities, end of year
- $373,267
- Net assets, end of year
- $1,033,139
- Net assets without donor restrictions
- $1,033,139
- Gross receipts
- $1,042,500
- Employees
- 0
- Volunteers
- 4
- Year formed
- 2020
- State of legal domicile
- DE
From the e-filed returns the IRS publishes as XML (latest three processing years; amended returns replace the original). PDF copies at the IRS.
Officers, directors and key employees
As listed on the 990 for the year ended December 31, 2025, highest compensation first.
| Name | Title | Hours / week | Compensation |
|---|---|---|---|
| DONNA FRENCH | PRESIDENT Trustee or director, Officer | 5 | $0 |
| SACHIN MITTAL | VICE PRESIDE Trustee or director, Officer | 5 | $0 |
| DAVID KANG | TREASURER Trustee or director, Officer | 5 | $0 |
| MONICA ADAMS | DIRECTOR Trustee or director | 5 | $0 |
990 for the year ended December 31, 2024: 4 people
| Name | Title | Hours / week | Compensation |
|---|---|---|---|
| DONNA FRENCH | PRESIDENT Trustee or director, Officer | 5 | $0 |
| SACHIN MITTAL | VICE PRESIDE Trustee or director, Officer | 5 | $0 |
| DAVID KANG | TREASURER Trustee or director, Officer | 5 | $0 |
| MONICA ADAMS | DIRECTOR Trustee or director | 5 | $0 |
990 for the year ended December 31, 2023: 4 people
| Name | Title | Hours / week | Compensation |
|---|---|---|---|
| DONNA FRENCH | PRESIDENT Trustee or director, Officer | 5 | $0 |
| SACHIN MITTAL | VICE PRESIDE Trustee or director, Officer | 5 | $0 |
| DAVID KANG | TREASURER Trustee or director, Officer | 5 | $0 |
| MONICA ADAMS | DIRECTOR Trustee or director | 5 | $0 |
Address and contacts
- Address (IRS master file)
- 3855 SW 153RD DR, BEAVERTON, OR 97003-5105
- Principal officer (990 for 2025)
- DONNA FRENCH, 3855 SW 153RD DRIVE, BEAVERTON, OR 97003
- Signed the 990
- DONNA FRENCH, PRESIDENT
- Phone
- (503) 619-0505
- Website
- SUBCUTANEOUSCONSORTIUM.ORG
- Return prepared by
- SKCPA & CO
Mission
OUR MISSION IS TO COLLABORATIVELY ADVANCE THE MOST PRESSING ISSUES AND OPPORTUNITIES IN SUBCUTANEOUS DOSAGE AND DELIVERY IN A PRECOMPETITIVE MANNER.
Program accomplishments
- A.PATIENT PREFERENCE & EXPERIENCE: COMPLETED THE DESIGN AND DEVELOPMENT OF THE CONJOINT TOOL AND SURVEY ON PATIENT PREFERENCE FOR SUBCUTANEOUS DRUG DELIVERY; FIELDING IS COMPLETE WITH OVER 500 RESPONSES RECORDED FROM THE US, EU, AND JAPAN, AND ANALYSIS IS UNDERWAY. B.HIGH DOSE HIGH VOLUME: COMPLETED AN INDUSTRY-WIDE SURVEY ON "HARMONIZATION OF PAIN METHODOLOGIES FOR SC ADMINISTRATION-; DRAFT MANUSCRIPT "INTEGRATED CMC ROAD MAP FOR DEVELOPMENT OF HDHV PRODUCTS- AND THE "HDHV SELECTION CRITERIA MATRIX" ARE EXPECTED TO BE PUBLISHED IN 2026 FOLLOWING INTERNAL SC CONSORTIUM REVIEW. C.CLINICAL DESIGN & REGULATORY STRATEGY: PUBLISHED A CROSS-COMPANY SURVEY MANUSCRIPT ON CLINICAL AND REGULATORY STRATEGY IN THE JOURNAL OF CONTROLLED RELEASE AND CONDUCTED A WORKSHOP ON "DEVELOPMENT PATHWAYS AND CONSIDERATIONS FOR SUBCUTANEOUS BIOLOGIC FORMULATIONS" AT THE CRS 2025 ANNUAL MEETING & EXPOSITION IN PHILADELPHIA. D.SUSTAINABILITY: COMPLETED AND PRESENTED RESULTS OF THE INDUSTRY BENCHMARKING SURVEY AT MULTIPLE CONFERENCES THROUGHOUT THE YEAR, INCLUDING A POSTER PRESENTATION AT THE PDA UPS CONFERENCE IN VIENNA, AND SUBMITTED A MANUSCRIPT FOR PUBLICATION IN THE ON-DRUG DELIVERY JOURNAL. E.IMMUNOGENICITY: ENHANCED SC CONSORTIUM AWARENESS BY HIGHLIGHTING IMMUNOGENICITY SUB-TEAM ACTIVITIES AT THE IMMUNOGENICITY AND BIOASSAY SUMMIT, AUTHORED THE IMMUNOGENICITY PORTION OF "DEBUNKING THE MYTHS OF SC DELIVERY,- AND EXPECTS MANUSCRIPT SUBMISSION BEFORE YEAR-END. F.BIOAVAILABILITY: SUBMISSION OF "DEBUNKING THE MYTHS OF SC DELIVERY," DESCRIBING ADVANCEMENTS AND OPPORTUNITIES IN SC BIOAVAILABILITY, TO THE JOURNAL OF CONTROLLED RELEASE; A SECOND PUBLICATION, "PREDICTING HUMAN SUBCUTANEOUS BIOAVAILABILITY OF MONOCLONAL ANTIBODIES USING A NOVEL OPEN FLOW MICROPERFUSION (OFM) PORCINE MODEL," IS UNDER REVIEW.
What it must file and when
IRS records say it files Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N. Its accounting year ends in December, so each return is due on the 15th day of the 5th month after that.
| Tax year | Year ended | Due | IRS public records |
|---|---|---|---|
| 2025 | December 31, 2025 | May 15, 2026 | 990 on file |
| 2024 | December 31, 2024 | May 15, 2025 | 990 on file |
| 2023 | December 31, 2023 | May 15, 2024 | 990 on file |
IRS record
- EIN
- 85-0837695
- Tax-exempt status
- 501(c)(6): Business league or chamber of commerce
- Donations deductible
- No
- Exempt since
- 2022
- Accounting year ends
- December
- Files
- Form 990 or 990-EZ
- Category (NTEE)
- Community improvement and capacity building (S46)
- Assets (IRS master file)
- $1,406,406
- Income (IRS master file)
- $1,042,500
Filing history
| Form | Year ended | Revenue | Expenses | Assets | Return |
|---|---|---|---|---|---|
| 990 | December 2025 | $1,042,500 | $862,745 | $1,406,406 | XML |
| 990 | December 2024 | $719,723 | $491,843 | $1,156,608 | XML |
| 990 | December 2023 | $760,000 | $769,199 | $901,226 | XML |
| 990 | December 2022 | $406,250 | $537,991 | $685,644 | IRS |
| 990 | December 2021 | – | – | – | IRS |
| 990 | December 2020 | – | – | – | IRS |
990-N: the IRS bulk file holds only the latest e-Postcard per organization; earlier years come from archived copies of that file since 2020 and can have gaps (the IRS e-Postcard search lists every one). 990, 990-EZ, 990-PF, 990-T: every e-filed return in the IRS e-file index since 2019; XML for the latest three processing years, amounts from the IRS Statistics of Income extracts before that. PDF copies and determination letters at the IRS (search EIN 85-0837695).
Questions about SUBCUTANEOUS DRUG DEVELOPMENT & DELIVERY CONSORTIUM INC
- What is the EIN of SUBCUTANEOUS DRUG DEVELOPMENT & DELIVERY CONSORTIUM INC?
- The employer identification number (EIN) of SUBCUTANEOUS DRUG DEVELOPMENT & DELIVERY CONSORTIUM INC is 85-0837695.
- Is SUBCUTANEOUS DRUG DEVELOPMENT & DELIVERY CONSORTIUM INC tax-exempt?
- Yes. The IRS lists it as tax-exempt under section 501(c)(6) since 2022.
- Are donations to SUBCUTANEOUS DRUG DEVELOPMENT & DELIVERY CONSORTIUM INC tax-deductible?
- No. The IRS master file says contributions to it are not deductible.
- Which annual return does SUBCUTANEOUS DRUG DEVELOPMENT & DELIVERY CONSORTIUM INC file?
- Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N.
- When is the next return of SUBCUTANEOUS DRUG DEVELOPMENT & DELIVERY CONSORTIUM INC due?
- The return for tax year 2026 (the year ending December 31, 2026) is due May 17, 2027. Form 8868 extends it by six months; the 990-N cannot be extended.
- When did SUBCUTANEOUS DRUG DEVELOPMENT & DELIVERY CONSORTIUM INC last file with the IRS?
- The latest return in the IRS public files is the 990 for the year ended December 2025.
- Who is the principal officer of SUBCUTANEOUS DRUG DEVELOPMENT & DELIVERY CONSORTIUM INC?
- The 990 for the year ended December 31, 2025 names DONNA FRENCH.
- Who are the officers and directors of SUBCUTANEOUS DRUG DEVELOPMENT & DELIVERY CONSORTIUM INC?
- The 990 for the year ended December 31, 2025 lists 4 people; 0 received compensation from the organization.
- How much revenue does SUBCUTANEOUS DRUG DEVELOPMENT & DELIVERY CONSORTIUM INC have?
- On its 990 for the year ended December 31, 2025 it reported revenue of $1,042,500, expenses of $862,745 and total assets of $1,406,406 at year end.
Other nonprofits in BEAVERTON
- FIDO ALLIANCE INC EIN 45-4948949 · last filed 990 for 2024
- USB IMPLEMENTERS FORUM INC EIN 93-1296452 · last filed 990 for 2024
- PCI SIG EIN 93-1288657 · last filed 990 for 2024
- THE KHRONOS GROUP INC EIN 82-0561169 · last filed 990 for 2024
- INFRASTRUCTURE MASONS INC EIN 81-3847379 · last filed 990 for 2025
- HDMI FORUM INC EIN 45-3632278 · last filed 990 for 2024
- CAR CONNECTIVITY CONSORTIUM LLC EIN 45-2387759 · last filed 990 for 2024
- ULTRA ACCELERATOR LINK CONSORTIUM INC EIN 33-1375615 · last filed 990 for 2025
All nonprofits in BEAVERTON · Oregon · Community improvement and capacity building